Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study
Authors:
- 28 May 2022
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (7) , 1435-1445
Abstract
Due to several issues, standard treatments are not recommended for asymptomatic patients with moderate immune thrombocytopenia (ITP). Since platelet responses are reported in some patients with Helicobacter pylori (H. pylori)-positive ITP after eradication, we conducted a multicenter, phase 3 study to evaluate the safety and efficacy of recently established sequential eradication for these patients having moderate thrombocytopenia. Persistent or chronic ITP patients with platelet count (30 × 103 ~ 80 × 103/μL) and confirmed active H. pylori infection were randomly assigned to a treatment and a control group. The former received 10-day sequential treatment. Eradication was assessed by urea breath test at 3 months after treatment. Primary endpoint was the overall platelet response rate at 3 months in successfully eradicated treatment group and control group. Secondary endpoints were platelet response time, H. pylori eradication success rate, etc. The patient enrollment terminated early because of the change of national insurance and treatment guideline for H. pylori-positive patients in Korea during the study. Of the 28 H. pylori-positive ITP patients, 17 were randomized to the treatment group, and eradication was achieved for 15 (88.2%) at 3 months, and seven in control group after withdrawal. Statistically, significant difference in platelet response rates between the two groups were observed (p = 0.017). Our study verifies that H. pylori eradication was an effective ITP treatment for patients with H. pylori-associated moderate ITP. This sequential eradication regimen showed not only a high H. pylori eradication rate, but also a remarkable platelet response for ITP patients. Trial registration number and date of registration for these prospectively registered trials is ClinicalTrials.gov number, NCT03177629 and June 6, 2017.Keywords
This publication has 51 references indexed in Scilit:
- Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopeniaBlood, 2011
- Sequential and Concomitant Therapy With Four Drugs Is Equally Effective for Eradication of H pylori InfectionClinical Gastroenterology and Hepatology, 2010
- Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic reviewHaematologica, 2009
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profilesBlood, 2007
- The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysisGut, 2007
- An African origin for the intimate association between humans and Helicobacter pyloriNature, 2007
- Immune Response to CagA Protein is Associated with Improved Platelet Count After Helicobacter pylori Eradication in Patients with Idiopathic Thrombocytopenic PurpuraHelicobacter, 2007
- Platelet Activation in Helicobacter pylori-Associated Idiopathic Thrombocytopenic Purpura: Eradication Reduces Platelet Activation but Seldom Improves Platelet CountsActa Haematologica, 2006
- Implications for Induction of Autoimmunity via Activation of B-1 Cells byHelicobacter pyloriUreaseInfection and Immunity, 2006